MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.
MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.
复制标题
DOI：
10.1016/j.cjca.2017.01.001
复制
发表时间：
2017-03
期刊：
影响因子：
--
通讯作者：
Rayner KJ
中科院分区：
文献类型：
--
作者：
Laffont B;Rayner KJ
MicroRNA是短的非编码RNA，在人类中表达并参与基因表达的序列特异性转录后调节。它们已经成为广泛的生物过程中的关键参与者，并且它们的表达和/或功能的变化与大量的人类疾病有关。动脉粥样硬化及其相关的临床并发症，如心肌梗塞或中风，是西方世界死亡的主要原因。越来越多的实验证据表明，microRNA在调节动脉粥样硬化发展相关的细胞和分子过程中发挥着关键作用，从危险因素到斑块的发生和进展，直至动脉粥样硬化斑块破裂。在这篇综述中，我们将重点关注microRNA如何影响动脉粥样硬化生物学，以及microRNA的潜在临床应用，这些microRNA正在开发为一个不断增长的行业的靶点和治疗方法，希望利用RNA引导的基因调控的力量来对抗疾病和感染。
MicroRNAs are short non-coding RNAs, expressed in humans and involved in sequence-specific post-transcriptional regulation of gene expression. They have emerged as key players in a wide array of biological processes, and changes in their expression and/or function have been associated with plethora of human diseases. Atherosclerosis and its related clinical complications, such as myocardial infarction or stroke, represent the leading cause of death in the western world. Accumulating experimental evidence has revealed a key role for microRNAs in regulating cellular and molecular processes related to atherosclerosis development, ranging from risk factors, to plaque initiation and progression, up to atherosclerotic plaque rupture. In this review, we will focus on how microRNAs can influence atherosclerosis biology, as well as the potential clinical applications of microRNAs which are being developed as both targets and therapeutics for a growing industry hoping to harness the power of RNA-guided gene regulation to fight disease and infection.